Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse
Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse
This study will evaluate the effect of pessary therapy, with and without Solifenacin
 (Vesicare), on symptoms of over active bladder and bladder function in women with overactive
 bladder symptoms and pelvic organ prolapse.

 Study Hypotheses:

 Null hypothesis, HO: Reduction of anterior vaginal wall prolapse and treatment with
 solifenacin does not improve overactive bladder symptoms more than reduction of anterior
 vaginal wall prolapse and placebo.

 Alternate hypothesis, HA: Reduction of anterior vaginal wall prolapse and treatment with
 solifenacin does improve overactive bladder symptoms more than reduction of anterior vaginal
 wall prolapse and placebo.
Pelvic organ prolapse (POP) affects approximately half of all women over age 501. The most
 common type of POP is anterior vaginal wall prolapse. Symptoms associated with POP include:
 voiding dysfunction, defecatory dysfunction and vaginal bulge symptoms. Treatments for pelvic
 organ prolapse include among other options, vaginal pessary or surgery. Several studies have
 documented improved vaginal bulge symptoms in women treated with a pessary2,3,4; however,
 data are sparse regarding the effect of pessaries on lower urinary tract symptoms,
 specifically with regard to over active bladder symptoms.

 Overactive bladder, observed in approximately 40% of women 50 years of age or older, is very
 common in women with pelvic organ prolapse. Two retrospective studies have shown improvement
 in women with overactive bladder symptoms following treatment with a vaginal pessary. One
 study (using a non-validated questionnaire) found that, at two month follow-up, patients
 successfully fitted with a pessary experienced a reduction in slightly less than half of
 their urge incontinence symptoms.5 A second study (using the Sheffield pelvic organ prolapse
 symptom questionnaire), revealed that 4 months after insertion of a pessary, 38% of patients
 experienced reduced urinary urgency, and 29% experienced reduced urge urinary incontinence6.
 Despite these data, many women stop using a pessary secondary to complaints of increased
 urine incontinence. More information is needed on pessary therapy impact on bladder function.

 Specific Aim(s):

 This study will prospectively evaluate women with pelvic organ prolapse and overactive
 bladder symptoms treated with either

 1. a pessary and solifenacin, or

 2. a pessary and placebo. We will assess the effects of these therapies on overactive
 bladder symptoms over the course of the 14-week study.
Inclusion Criteria:

 -  Female

 -  Age ≥ 18 years

 -  Have experienced symptoms of overactive bladder (e.g., urinary urgency, frequency, or
 urge incontinence) for at least 3 months. Specifically women must average 8 or more
 voids in 24 hours and have 3 or more episodes of urinary urgency or urge incontinence
 over the 72 hours when the diary is being completed.

 -  A practitioner trained in the pelvic organ prolapse quantification examination will
 evaluate each woman's pelvic organ support and vaginal dimensions. Women with a stage
 1 or greater vaginal prolapse will be eligible for the study.

 Exclusion Criteria:

 -  The presence of factors that would contraindicate use of antimuscarinic medications
 (e.g. urine retention, narrow angle glaucoma, uncontrolled constipation, dementia)

 -  An existing condition that would contraindicate use of a vaginal pessary (e.g.,
 patient's vaginal length <6 cm)

 -  Patient is currently using a vaginal pessary.

 -  Patient is unable to tolerate an object in vagina

 -  Patient has a history of cervical, vaginal or endometrial cancer

 -  Patient is not able to speak English

 -  Patient is currently using an anticholinergic medication, or has used one in the past
 30 days

 -  Patients with mixed urine incontinence that is predominantly stress urine incontinence
 (determined by their baseline PFDI)

 -  Patients with a known allergy to solifenacin.

 -  Patients with severe hepatic impairment.